Jan 25 (Reuters) - CTI Biopharma Corp:
* CTI BIOPHARMA PROVIDES CORPORATE AND EUROPEAN REGULATORY UPDATE
* CTI BIOPHARMA - WAS GRANTED 3 MONTH EXTENSION TO SUBMIT ITS RESPONSE TO DAY 120 LIST OF QUESTIONS FOR HUMAN USE OF EMA, REGARD TO MAA FOR PACRITINIB
* CTI BIOPHARMA CORP - CO ANTICIPATES SUBMITTING ITS RESPONSE TO D120 LOQ IN MAY 2018
* CTI BIOPHARMA CORP - CO REINCORPORATED IN STATE OF DELAWARE, DELISTED FROM BORSA ITALIANA MTA EXCHANGE Source text for Eikon: Further company coverage:
 